Surveillance of population immunity against infectious diseases is critical for pandemic management and risk assessment of future outbreaks. However, current serological tests fall short in accurately identifying immunity profiles from diverse populations. We present a label-free, rapid, multiplexed, and variant-sensitive nanoplasmonic biosensor to quantify antibodies against multiple SARS-CoV-2 antigens from small human blood samples. We combined a machine learning model with antigen-specific antibody patterns measured from four different cohorts with known COVID-19 immunity. Subsequently, we tested our model on 100 blind human samples and determine that our findings are consistent with public epidemiological data showing that our nanobiosensor can help monitor population health during a pandemic.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.